Caris Life Sciences Identifies Key Resistance Mechanisms to Trastuzumab Deruxtecan in Metastatic Breast Cancer
I'm PortAI, I can summarize articles.
Caris Life Sciences Inc. has published a study in Nature’s npj Breast Cancer journal on resistance mechanisms to trastuzumab deruxtecan (T-DXd) in metastatic breast cancer. Analyzing data from 2,799 patients, the study identified ERBB2 (HER2) and ABCC1 as key predictors of survival. Higher ERBB2 expression linked to better outcomes, while higher ABCC1 correlated with worse outcomes. The research also noted increased ABCC1 and mutations in ERBB2, NFE2L2, KEAP1, and TOP1 in post-treatment samples, indicating potential acquired resistance pathways. The study's findings are already published.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments